BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene Ltd.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Halozyme (HALO) and Oncolytics Biotech (ONCY) with b...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Carole Madjo from Barclays maintained a Buy rating on Moncler S.p.A., with a price target of €62.00. According to TipRa...

Barclays Reaffirms Their Buy Rating on Moncler S.p.A. (0QII)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY) and Neurocrine (NBIX). O...

Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (ONCY) and Neurocrine (NBIX)

An update from Oncolytics Biotech ( ($ONCY) ) is now available. On April 6, 2026, Oncolytics Biotech announced it had scheduled a Type C meeting wi...

Oncolytics Plans FDA Meeting for Pelareorep SCAC Study

Truist Financial analyst Gregory Renza reiterated a Buy rating on BeOne Medicines today and set a price target of $412.00. According to TipRanks, R...

Truist Financial Remains a Buy on BeOne Medicines (ONC)

In a report released today, Chris Huang from UBS maintained a Hold rating on Moncler S.p.A., with a price target of €55.00. According to TipRanks, ...

UBS Sticks to Its Hold Rating for Moncler S.p.A. (0QII)

Traders can read the latest stock market happenings in our daily wrap-up.


Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories

Onconetix ( ($ONCO) ) has issued an update. Onconetix, Inc., a commercial-stage biotechnology firm specializing in men’s health and oncology diagno...

Onconetix Completes Reverse Stock Split to Maintain Listing

RBC Capital analyst Piral Dadhania maintained a Hold rating on Moncler S.p.A. on March 23 and set a price target of €59.00. The company’s shares cl...

RBC Capital Remains a Hold on Moncler S.p.A. (0QII)

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines has completed a phase 1 trial called “A Phase 1, Single...

BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study

An update from Onconetix ( ($ONCO) ) is now available. On March 18, 2026, Onconetix appointed veteran executive and independent director David Whit...

Onconetix Appoints New CEO and Refreshes Board Leadership

Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. Oncolytics Biotech will present new mechanistic and translational data at the AACR 20...

Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1 study titled “A Phase 1, Randomized, Double-Blind, Placebo ...

BeOne Medicines Advances BG-A3004 Into First-in-Human Skin Disease Trial: What Investors Should Watch

Oncolytics Biotech ( ($ONCY) ) has issued an announcement. On March 19, 2026, Oncolytics Biotech announced that new mechanistic and translational d...

Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy

Bernstein analyst Rebecca Liang maintained a Buy rating on BeOne Medicines today and set a price target of $412.00. Liang covers the Healthcare sec...

Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)

Oncopeptides AB ( ($SE:ONCO) ) has issued an announcement. Oncopeptides AB has completed a partially guaranteed rights issue of approximately SEK 2...

Oncopeptides Raises SEK 190 Million in Partially Guaranteed Rights Issue

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The study “A Phase 1a/1b Study Investigating the Safety, Tolerability, ...

BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors

The latest update is out from Onco-Innovations Ltd. ( ($TSE:ONCO) ). Onco-Innovations Limited has closed a non-brokered private placement, issuing ...

Onco-Innovations Raises $1.22 Million in Completed Private Placement

Bernstein analyst Rebecca Liang maintained a Buy rating on BeOne Medicines today and set a price target of $412.00. According to TipRanks, Liang is...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ONC	$312.43	+2.83%	178.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ONC	$312.43	+2.8%	178.86K
3
4
5
6

ONC

ONC

No Data Available

Get BeiGene Ltd. Data in Excel

Get BeiGene Ltd. Data in Excel